Clearside Biomedical (CLSD) AI Stock Analysis

• Market Cap: $19.73M
• Dividend Yield: N/A
• Average Volume (3M): 64.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: -44.63%
• EPS Growth: 26.79%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.50
• Shares Outstanding: 5,234,021
• 10 Day Avg. Volume: 36,098
• 30 Day Avg. Volume: 64,393
• PEG Ratio: 0.18
• Price to Book (P/B): -1.80
• Price to Sales (P/S): 42.14
• P/FCF Ratio: -2.73
• Enterprise Value/Market Cap: 5.53
• Enterprise Value/Revenue: 26.20
• Enterprise Value/Gross Profit: 29.62
• Enterprise Value/Ebitda: -6.02
• 1Y Price Target: $45.00
• Price Target Upside: 1053.85% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 42 Neutral
• Price Target: $4.00 ▲(2.56% Upside)

Clearside Biomedical faces significant financial challenges, with declining revenues and consistent losses being the most impactful factors. The technical analysis indicates a bearish trend, and the valuation is poor due to a negative P/E ratio. These factors collectively result in a low overall stock score.

Positive Factors

Innovative Drug Delivery Platform

The SCS Microinjector offers a unique method for delivering drugs directly to the eye, potentially enhancing treatment efficacy and providing a competitive edge in ocular therapeutics.

Strategic Partnerships

Strategic partnerships can provide Clearside with additional resources, expertise, and market access, supporting long-term growth and innovation in drug development.

Product Pipeline

A strong product pipeline indicates potential for future revenue growth and market expansion, as new therapies can address unmet needs in ocular diseases.

Negative Factors

Declining Revenue

Declining revenue poses a significant risk to Clearside's financial stability, limiting its ability to invest in R&D and sustain operations without external funding.

Negative Cash Flow

Negative cash flow highlights challenges in generating sufficient cash from operations, potentially leading to increased reliance on debt or equity financing.

Financial Instability

Negative equity and high liabilities suggest solvency concerns, which could impact Clearside's ability to secure future financing and sustain long-term operations.

Clearside Biomedical Business Overview & Revenue Model

Company Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

How the Company Makes Money

Clearside Biomedical generates revenue primarily through the commercialization of its products, notably Xipere, which is sold to healthcare providers and patients. The company also explores partnerships and collaborations with larger pharmaceutical companies, which may include licensing agreements or co-development deals that provide upfront payments, milestone payments upon achieving development goals, and royalties on sales. Additionally, Clearside may benefit from research grants or funding from government and non-profit organizations aimed at supporting innovative treatments in eye care.

Clearside Biomedical Financial Statement Overview

Summary

Clearside Biomedical's financials demonstrate significant challenges, with declining revenues, consistent losses, and a strained balance sheet. The company's reliance on external financing, negative equity, and inability to generate positive cash flows present substantial financial risks.

Income Statement

The company has experienced declining revenue over the years, with total revenue dropping to zero by 2024. This is coupled with persistent negative net income, indicating operational challenges. The absence of revenue growth and consistent losses suggest significant difficulties in generating profit.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating financial instability. High liabilities relative to assets and negative equity highlight potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities reflect leverage risks.

Cash Flow

The cash flow statement indicates negative free cash flow and operating cash flow over the years, reflecting challenges in cash generation from operations. Though financing activities provided some relief, reliance on external funding is unsustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.17M	1.66M	8.23M	1.33M	29.57M	7.89M
Gross Profit	3.69M	1.51M	7.87M	1.12M	29.57M	7.89M
EBITDA	-18.12M	-24.35M	-23.06M	-29.46M	554.00K	-17.70M
Net Income	-27.71M	-34.35M	-32.48M	-32.95M	376.00K	-18.21M
Balance Sheet
Total Assets	15.33M	25.13M	34.02M	51.30M	42.90M	19.32M
Cash, Cash Equivalents and Short-Term Investments	9.38M	20.02M	28.92M	48.26M	30.44M	17.29M
Total Debt	533.00K	52.47M	43.00M	35.26M	675.00K	1.98M
Total Liabilities	64.07M	63.98M	49.93M	40.70M	4.93M	10.56M
Stockholders Equity	-48.73M	-38.85M	-15.91M	10.61M	37.98M	8.76M
Cash Flow
Free Cash Flow	-22.22M	-25.68M	-19.91M	-13.61M	-10.73M	-13.18M
Operating Cash Flow	-21.73M	-24.70M	-18.14M	-13.37M	-10.73M	-13.12M
Investing Cash Flow	10.85M	-638.00K	-1.78M	-246.00K	0.00	-55.00K
Financing Cash Flow	2.02M	16.44M	414.00K	31.33M	23.78M	7.87M

Clearside Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSD, the sentiment is Negative. The current price of 3.9 is below the 20-day moving average (MA) of 4.06, below the 50-day MA of 4.64, and below the 200-day MA of 10.41, indicating a bearish trend. The MACD of -0.23 indicates Negative momentum. The RSI at 43.83 is Neutral, neither overbought nor oversold. The STOCH value of 28.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLSD.

Clearside Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CING	47 Neutral	$20.74M	―	-417.77%	―	―	96.32%
CLSD	42 Neutral	$19.73M	-0.70	―	―	-44.63%	26.79%
XTLB	39 Underperform	$11.51M	―	―	―	―	65.38%
APVO	38 Underperform	$20.85M	>-0.01	-437.34%	―	―	98.45%
RLYB	35 Underperform	$23.06M	―	-66.12%	―	154.52%	47.84%
PCSA	29 Underperform	$15.41M	―	-212.38%	―	―	57.99%

Clearside Biomedical Corporate Events

Clearside Biomedical Regains Nasdaq Compliance as of October 2025

Clearside Biomedical, Inc. has successfully regained compliance with Nasdaq’s Minimum Bid Price Requirement as of October 6, 2025. This follows a series of events starting from February 7, 2025, when the company was notified of non-compliance due to its stock price falling below $1.00 for 30 consecutive days. After implementing a reverse stock split and presenting a compliance plan to the Nasdaq Hearings Panel, the company has now met the necessary criteria to maintain its listing, closing the matter.

The most recent analyst rating on (CLSD) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Clearside Biomedical Announces Reverse Stock Split Plan

On September 10, 2025, Clearside Biomedical, Inc. filed a Certificate of Amendment to implement a one-for-fifteen reverse stock split and reduce its authorized common stock from 400 million to approximately 26.67 million shares, effective September 12, 2025. This strategic move, approved by stockholders and the board, will proportionately adjust stock options, restricted stock units, and warrants, with trading on a split-adjusted basis commencing on September 15, 2025, potentially impacting the company’s market positioning and shareholder value.

The most recent analyst rating on (CLSD) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Clearside Biomedical Announces Reverse Stock Split

On September 10, 2025, Clearside Biomedical, Inc. filed a Certificate of Amendment to implement a one-for-fifteen reverse stock split and reduce the total number of authorized shares from 400,000,000 to 26,666,666, effective September 12, 2025. This move, approved by stockholders and the board, aims to adjust the company’s stock structure, affecting all outstanding shares and stock options proportionately, with trading on a split-adjusted basis beginning September 15, 2025.

The most recent analyst rating on (CLSD) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Clearside Biomedical Secures $3M with Agreement Amendment

On September 4, 2025, Clearside Biomedical, Inc. amended its agreements with Healthcare Royalty Partners IV, L.P., resulting in an additional $3 million payment to Clearside and adjustments to the terms of royalty payments and foreclosure rights. This amendment reflects strategic financial maneuvers to optimize Clearside’s capital structure and secure its technology assets, potentially enhancing its market position and stakeholder confidence.

The most recent analyst rating on (CLSD) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Clearside Biomedical Approves Reverse Stock Split Proposal

On August 28, 2025, Clearside Biomedical received a notice from Nasdaq regarding non-compliance with the Market Value of Listed Securities requirement, giving the company until February 24, 2026, to regain compliance or face potential delisting. Additionally, on August 29, 2025, the company held a special meeting where stockholders approved a proposal for a reverse stock split to address a previous non-compliance issue related to the minimum bid price requirement, aiming to maintain its listing on Nasdaq.

The most recent analyst rating on (CLSD) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Clearside Biomedical Announces New Chairperson Appointment

On February 7, 2025, Clearside Biomedical was notified by Nasdaq about non-compliance with the minimum bid price requirement, risking delisting. The company plans to request a hearing to maintain its listing and has filed for a reverse stock split to regain compliance. Additionally, Anthony Gibney resigned as Chairperson on August 11, 2025, succeeded by Clay B. Thorp.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Clearside Biomedical’s Phase 2b Study on CLS-AX: A New Hope for AMD Treatment

Clearside Biomedical Inc. recently completed a clinical study titled ‘ODYSSEY: A Phase 2b Study of Suprachoroidally Administered CLS-AX in Participants With Neovascular Age-Related Macular Degeneration.’ The study aimed to evaluate the safety and efficacy of CLS-AX, a new treatment for neovascular age-related macular degeneration (AMD), a leading cause of vision loss. This study is significant as it explores an alternative to the current standard anti-VEGF therapies.